Xiong Lab
Empowering drug discovery with new covalent chemistry
What we do:
Discover new covalent chemistry for targeting amino acids like cysteine, aspartate, glutamate, lysine, etc., utilizing physical organic chemistry and pharmacokinetics to finely tune the reactivity, stability, and selectivity of covalent warheads.
High-throughput screening: We have access to an in-house small chemical diversity library of 35,000 compounds, a 5,000-compound TargetMol bioactive library, and an additional 1,800 covalent compounds from Enamine. An example project includes screening first-in-class chemical probes to sensitize immune checkpoint inhibitors for ‘cold tumors’ using high-throughput methods.
Structure-based drug design: We are actively collaborating with structural biologists and leveraging advanced computational tools to optimize lead molecules as potential drug candidates.
Molecules We Discovered
TTC-352
Estrogen Receptor Partial Agonist
Phase I/II clinical trials
Clinical trial ID: NCT03201913
J. Med. Chem. 2016, 59, 219–237
